Another stock that's just starting to enter breakout territory is Celldex Therapeutics (CLDX - Get Report), which is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. This stock has been red hot so far in 2013, with shares up a whopping 90%.
If you take a look at the chart for Celldex Therapeutics, you'll notice that that this stock has been trending sideways in a consolidation chart pattern for the last two months, with shares moving between $11.01 on the downside and $12.49 on the upside. Shares of CLDX recently formed a triple bottom chart pattern just above $11 a share. This stock has now started to break out above some near-term overhead resistance levels at $12.34 to $12.49 a share with solid upside volume flows.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts